A Phase I, Open-Label, Dose Finding Study of CC-90002, a Monoclonal Antibody Directed Against CD47, in Subjects With Advanced Solid and Hematologic Cancers
Phase of Trial: Phase I
Latest Information Update: 17 May 2017
At a glance
- Drugs CC 90002 (Primary)
- Indications Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Celgene Corporation
- 09 May 2017 Planned number of patients changed from 100 to 65.
- 16 Aug 2016 Planned primary completion date changed from 1 Dec 2017 to 1 Jan 2018.
- 15 Sep 2015 Planned End Date changed from 1 Dec 2017 to 1 Jan 2018 as per ClinicalTrials.gov record.